The FDA published its first-ever guidance on AI in drug development in January 2025. A 7-step credibility framework for how AI models should be evaluated in pharmaceutical submissions.
Then in January 2026, the EMA and FDA jointly released 10 guiding principles for AI in medicine development.
Two regulatory bodies. Two continents. One message: AI in pharma is not a maybe anymore.
And most mid-market pharma companies I talk to are still trying to figure out where to start.
The numbers tell the real story.
It is sitting in your QMS, your LIMS, your deviation logs. Right now. Batch record review. Regulatory document prep. Supplier risk monitoring. Analytical data review.
But here is the problem.
67% of companies are stuck in what I call pilot purgatory. Running a proof of concept here. Testing a tool there. Never scaling. Never integrating. Never getting to the part where AI actually changes how the business operates.
Only 23% are scaling AI beyond pilot.
Forrester's data makes this even sharper. Only 15% of AI decision-makers reported an actual EBITDA lift from AI in the past 12 months. And enterprises are now deferring 25% of planned AI spend into 2027.
Not because AI doesn't work. Because they weren't ready for it.
Pharma has a readiness problem, not a technology problem.
I have spent enough time in regulated environments to know that pharma is different. You cannot just plug in an AI tool and hope for the best.
Every implementation touches GxP validation. 21 CFR Part 11 data integrity. EU Annex 11 standards. Audit trails that regulators will actually look at.
Your data lives in disconnected systems. LIMS over here. ERP over there. QMS somewhere else. Document management in a fourth place. I am oversimplifying the data problem, honestly. Some companies have one system that works beautifully. The issue is it never talks to the three other systems that AI actually needs.
And the talent gap is real. Finding someone who understands both AI capabilities and pharmaceutical operations at the mid-market level is nearly impossible. Most teams lack the internal literacy to even evaluate vendors, let alone implement solutions compliantly.
This is not a "buy a tool" problem. This is a foundation problem.
The FDA is not waiting for you to be ready.
That guidance document was not a suggestion. It was a signal.
The FDA's own NLP pilot analyzed 12,000 pages of study reports in hours. They are using this technology themselves. They are building the framework for how they expect you to use it.
What readiness actually looks like in pharma.
It starts with an honest assessment across seven dimensions. But not all seven are equal.
Governance is where pharma companies get burned first. Your AI validation framework, your data integrity protocols, your audit trail requirements. Get this wrong and nothing else matters. I have seen companies spend six months building an AI workflow only to discover their validation approach would not survive a routine audit. That is six months and a lot of budget you do not get back.
Data is the other non-negotiable. If your LIMS, ERP, and QMS are siloed, no AI tool will save you. Data architecture has to come before everything else. And I mean architecture, not just cleanup. You need to know what data lives where, what talks to what, and where the gaps are before you even evaluate a vendor.
Process, Talent, Culture, Strategy, Technology. They all matter. But Governance and Data are where pharma companies either build the foundation or build on sand.
The CDMO Angle
CDMOs have an even bigger version of this problem. You are managing multiple client pipelines, parallel regulatory requirements, and every client relationship adds another layer of data governance. Grand View Research projects the CDMO market growing to $375 billion by 2031. The CDMOs that build AI readiness as a capability will win contracts their competitors cannot even bid on.
Here is what this really means.
The regulatory landscape moved. The technology is proven. The economics work.
The only variable left is whether your organization has the foundation to execute.
That is not a technology question. It is a readiness question.